Trial Profile
An Open-Label Study of Nevirapine Plus Combivir® (ZDV+3TC) Treatment in Women Who Have Previously Received a Nevirapine Regimen for the Prevention of Mother to Child Transmission (pMTCT) of HIV-1.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Lamivudine/zidovudine (Primary) ; Nevirapine (Primary)
- Indications HIV-1 infections; Pregnancy
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 31 Jan 2008 Status change from in progress to completed.
- 12 Nov 2006 New trial record.